1790 Article Views
Publication Date: 01 Jul 2009
Journal: Clinical Medicine Insights: Therapeutics
Baburhan Guldiken
Trakya University Medical Faculty, Department of Neurology, Edirne,Turkey.
Abstract
Migraine is a neurovascular disease, which pathogenesis is still unclear. It causes a severe headache and a substantial financial loss due to absenteeism, therefore, its effective treatment is particularly valuable. Triptans, selective 5HT1B and D receptor agonists, are effective treatment choices of acute migraine attacks. Migraine patients, who bear special conditions such as hypertension, hepatic or renal impairment, constitute a special subgroup of patients whose treatment with triptans has to be individually arranged. The review of Kalanuria and Peterlin, regarding the metabolism and efficacy of zolmitriptan in the abortive treatment of migraine, highlights many details of the use of zolmitriptan in migraine patients.
Discussion
No comments yet...Be the first to comment.
As the Editor-in-Chief of Clinical Medicine Insights: Trauma and Intensive Medicine, I experience an outstanding professional and timely support by the publisher, Libertas Academica, in all editorial matters.Dr Philip F. Stahel (Denver Health Medical Center, University of Colorado Denver, School of Medicine, Denver, CO, USA) What our authors say
Copyright © 2012 Libertas Academica Ltd (except open access articles and accompanying metadata and supplementary files.)